# 2026-10128: DEA Proposes Changes to Drug Quota Applications

2026-10128, Revision of Applications for Manufacturing and Procurement Quotas, is a Federal Register proposed rule from Justice Department, Drug Enforcement Administration published 2026-05-20, effective Comments must be received by July 20, 2026. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.; deemed significant under Executive Order 12866; PRIA reads it as touching household money (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2026-10128
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-10128
- Title: Revision of Applications for Manufacturing and Procurement Quotas
- Type: Proposed Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 29394
- Published: 2026-05-20
- Effective: Comments must be received by July 20, 2026. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.
- Comments close: 2026-07-20
- Significant: yes (FR_METADATA)
- Touches household money: yes
- Regulation identifier numbers: 1117-AB86
- Last updated: 2026-06-11

## In one line

DEA Proposes Changes to Drug Quota Applications

## Summary

The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.

## Abstract

The Drug Enforcement Administration (DEA) proposes to revise existing regulations relating to the management of quotas for schedule I and II controlled substances and the list I chemicals, ephedrine, pseudoephedrine, and phenylpropanolamine, to be utilized by DEA- registered manufacturers. This rule is being proposed to: restructure DEA's manufacturing and procurement quota regulations for more clarity and consistency; clarify which use-specific subcategories for quotas should be used for controlled substances that will be sold domestically and controlled substances that will be exported; and revise the applications for individual manufacturing and procurement quota. The changes are necessary to increase visibility into the controlled substance supply chain by providing DEA with more detailed information allowing the agency to react more precisely in preventing drug shortages; and to ensure that enough of the schedule I and II controlled substances and three list I chemicals can be manufactured to meet estimated scientific, medical, lawful export, and inventory needs. This rule also contains revisions to use gender neutral language and other non-substantive revisions.

## Effects PRIA read

- New Quota Application Timeline Reporting: cost, medium. If you are a bulk or non-bulk manufacturer applying for DEA quotas, you must provide new production-timeline details on quota applications (DEA Form 189 for bulk manufacturers; DEA Form 250 for non-bulk manufacturers). DEA lists the required items: desired individual manufacturing quota (bulk only)…
- Domestic vs. Export Quota Split: mixed, low. DEA will split certain quota subcategories so manufacturers must state whether quota is for domestic use or for lawful export. The rule bifurcates 'Quota for Commercial Sale', 'Quota for Product Development', and 'Quota for Packaging/Repackaging and Labeling/Relabeling' into domestic and export sub…
- Estimated Time and Dollar Burden: cost, low. DEA estimates the new information will add about 20 minutes per DEA Form 189 or 250 to complete, with a loaded median hourly cost of $89.42 for a purchasing manager, producing an estimated per-application cost of $29.81. Using 2022 application counts (875 Form 189 and 2,514 Form 250), DEA estimates…
- Better Data to Prevent Drug Shortages: benefit, medium. DEA says the new application information and subcategory changes will give the agency better visibility into manufacturing cycles and domestic vs. export use, enabling DEA to adjust quotas more quickly to anticipate and help prevent drug shortages that affect medical and scientific needs.
- Small-Entity Impact Finding: cost, low. DEA certifies under the Regulatory Flexibility Act that the proposed rule will not have a significant economic impact on a substantial number of small entities. DEA estimates the rule would affect 38 of 635 small entities in NAICS 325411 and 272 of 1,080 small entities in NAICS 325412, with estimat…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10
- [2026-22717](https://policyrisk.com/federal-register/2026-22717): Specific Listing for 3-Chloromethcathinone, A Currently Controlled Schedule I Substance, 2026-11-06

## Sources
- [2026-10128 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/20/2026-10128/revision-of-applications-for-manufacturing-and-procurement-quotas)
- [2026-10128 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-20/pdf/2026-10128.pdf)

## Related
- [Previous: 2026-10086, Extending the Compliance Deadline for the PFOA and PFOS Maximum Contaminant Lev…](https://policyrisk.com/federal-register/2026-10086)
- [Next: 2026-10161, Significant New Use Rules on Certain Chemical Substances (26-2); Extension of C…](https://policyrisk.com/federal-register/2026-10161)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-10128 (as of 2026-06-11).
